21 Apr 2008 : Column 1784W—continued
| Table Two: Proportion male and female screened for chlamydia by NCSP programme area for the period 1 April 2006 to 31 March 2007 |
| Programme area | Percentage male | Percentage female | Total( 1) |
|
Ashfield
|
46
|
54
|
28
|
|
Bedfordshire and Hertfordshire
|
23
|
77
|
2,009
|
|
Berkshire East
|
45
|
55
|
2,645
|
|
Birmingham
|
12
|
88
|
6,736
|
|
Bournemouth and Poole
|
34
|
66
|
693
|
|
Bradford and Airedale
|
17
|
83
|
1,048
|
|
Brent and Harrow
|
22
|
78
|
2,253
|
|
Brighton
|
17
|
83
|
5,736
|
|
Buckinghamshire
|
21
|
79
|
14
|
|
Cambridge and Peterborough
|
30
|
70
|
1,506
|
|
Camden and Islington
|
7
|
93
|
3,404
|
|
Central Lancashire
|
13
|
87
|
1,378
|
|
City and Hackney
|
0
|
100
|
(2)—
|
|
Cornwall
|
35
|
65
|
8,076
|
|
Coventry
|
18
|
82
|
1,908
|
|
Cumbria
|
0
|
100
|
(2)—
|
|
Dorset
|
61
|
39
|
594
|
|
Durham and Teeside
|
53
|
47
|
7,132
|
|
East Cheshire
|
14
|
86
|
3,922
|
|
East Kent
|
18
|
82
|
3,200
|
|
East Lancashire
|
22
|
78
|
482
|
|
East Yorkshire
|
37
|
63
|
757
|
|
Enfield and Haringey
|
19
|
81
|
1,874
|
|
Greater Manchester
|
17
|
83
|
7,866
|
|
Halton, St. Helens and Warrington
|
0
|
100
|
(2)—
|
|
Hampshire
|
39
|
61
|
5,791
|
|
Hastings
|
20
|
80
|
532
|
|
Hounslow
|
25
|
75
|
234
|
|
Hull
|
17
|
83
|
3,668
|
|
Lambeth and Southwark
|
16
|
84
|
9,463
|
|
Leeds
|
27
|
73
|
5,509
|
|
Leicester
|
21
|
79
|
211
|
|
Lewisham
|
18
|
82
|
6,498
|
|
Liverpool
|
14
|
86
|
11,456
|
|
Mid Essex
|
0
|
100
|
(2)—
|
|
Milton Keynes
|
19
|
81
|
2,793
|
|
Norfolk and Waveney
|
22
|
78
|
2,539
|
|
North Staffordshire
|
15
|
85
|
4,236
|
|
Northern Lincolnshire
|
32
|
68
|
132
|
|
Northumberland, Tyne and Wear
|
37
|
63
|
1,205
|
|
Nottingham
|
12
|
88
|
6,775
|
|
Plymouth
|
33
|
67
|
(2)—
|
|
Portsmouth
|
12
|
88
|
4,797
|
|
Sheffield
|
16
|
84
|
5,036
|
|
South East Essex
|
11
|
89
|
2,403
|
|
South Staffordshire
|
12
|
88
|
349
|
21 Apr 2008 : Column 1785W
|
Southampton
|
26
|
74
|
392
|
|
Suffolk
|
13
|
87
|
1,193
|
|
Tower Hamlets
|
0
|
100
|
(2)—
|
|
Wakefield District and Dewsbury, Batley
|
14
|
86
|
336
|
|
West Cheshire
|
8
|
92
|
1,777
|
|
West Kent
|
17
|
83
|
1,779
|
|
West Sussex
|
40
|
60
|
43
|
|
Wirral
|
14
|
86
|
5,242
|
|
York
|
30
|
70
|
3,572
|
|
Boots Pathfinder
|
22
|
78
|
11,729
|
|
Total
|
21
|
79
|
162,961
|
(1) Total number screened excluding screens with sex marked as unknown and unspecified.
(2) Cell sizes between 1 and 4 (and totals that would allow for them to be deduced) have been masked to prevent deductive disclosure in accordance with ONS guidelines.
Notes:
1. Data as of 27 February 2008.
2. The data from the NCSP are for screens outside of GUM clinics only and include screens from the Boots pathfinder project.
3. The data available from the NCSP are the number of screens done and not the number of patients screened. The number of screens is assumed to be a close proxy of the number of people screened.
4. The data only include those aged 13-24 years.
5. The data are for 1 April 2006 to 31 March 2007 because the NCSP receives data on a quarterly basis and follows the financial year.
6. The data provided are based on NCSP programme areas, not postcode of residence. The programme areas are geographically distinct areas formed by one or more primary care trusts and are responsible for coordinating local screening.
Source:
HPA-NCSP.
|
Chronic Fatigue Syndrome: Research
Mr. Maude:
To ask the Secretary of State for Health if he will establish an independent scientific committee to oversee research into myalgic encephalomyelitis/chronic fatigue syndrome. [199903]
Ian Pearson:
I have been asked to reply.
There are currently no plans to establish an independent scientific committee to oversee research into myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). However, the Medical Research Council (MRC) is planning to set up a panel of experts from different disciplines to look more closely at the area. The panel will come from varied fields including neuroscience, immunology, toxicology and imaging, and will involve interested parties and focus on the subtypes and causes of ME/CFS.
Mr. Maude:
To ask the Secretary of State for Health if he will take steps to ensure that Government funding for biomedical research on ME/CFS is equal to Government funding for psychological research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. [199904]
Ian Pearson:
I have been asked to reply.
The Medical Research Council (MRC) is committed to funding scientific research into all aspects of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) including evaluations of other treatments and studies into the biological and psychological basis of the condition. The amount provided by the MRC to each type of research depends on the quality and number of proposals received.
